It is usually administered as a subcutaneous injection once a week
Expected 12-month results include 15 to 20% body weight loss (65 to 100+ pounds for a 400-pound person), 6 to 10 inch waist circumference reduction, transformative improvement in daily functional capacity, and resolution or significant improvement of multiple obesity-related conditions
It is suggested that the main advantage of subcutaneous semaglutide lies in its weekly dosing, which may facilitate adherence to treatment, especially in patients who prefer a lower dosing frequency
Programs in this space typically prescribe GLP-1 receptor agonists such as semaglutide, or the dual agonist tirzepatide, either as FDA-approved brand products or compounded preparations
doi: 10.5713/ab.24.0257 81 AbramsETMillerEM
Third, the dose-response relationship is clear: higher target doses produce greater weight reduction, with 12mg weekly producing the peak 24.2% result